Patrick Forde, MBBCh, offers crucial perspectives on breakthroughs in Non-Small Cell Lung Cancer from ESMO 2023.
EP. 1: CheckMate 77T: Perioperative Immunotherapy in Resectable NSCLC
Patrick Forde, MBBCh, shares insights on perioperative immunotherapy in the CheckMate-77T study presented at ESMO 2023.
EP. 2: Evolving NSCLC Landscape: Comparing Recent Updates in Neoadjuvant and Perioperative Immunotherapy
An expert comparison of recent data on neoadjuvant and perioperative immunotherapy in resectable early-stage NSCLC, including CheckMate 77T, CheckMate-816, and KEYNOTE-671.
EP. 3: Updates in ALK+ NSCLC: ALINA Trial at ESMO 2023
Patrick Forde, MBBCh, discusses ALK rearrangement in NSCLC and highlights ALINA trial results from ESMO 2023.
EP. 4: Lessons from LIBRETTO-431 Trial in RET+ NSCLC
An overview of data presented at ESMO 2023 on the LIBRETTO-431 trial of selpercatinib in RET+ NSCLC.
EP. 5: PAPILLON Trial Insights: ESMO 2023
Patrick Forde, MBBCh, discusses advances in EGFR Exon 20 insertion-mutated NSCLC.
EP. 6: Innovations Needed and Future Directions in Treatment of NSCLC
Concluding thoughts on data presented at ESMO 2023, and innovations still needed for improved survival of NSCLC—provided by Patrick Forde, MBBCh.
2 Clarke Drive Cranbury, NJ 08512